Insights Accelerated
Meet our accelerators: Ragnar Strigård & Njord
Recent interview with Ragnar Strigård explores how his accelerator model helps life science founders transform high‑potential research into fundable, scalable companies.
Beyond the Science: Decoding the "Globally Street Smart" Approach to Negotiation
In a recent interview, Helena shared her perspective on why authenticity, a tolerance for friction, and the ability to "read the room" from a macro perspective are the tools to thrive in negotiations.
The Hard Middle of Biotech
Insights Accelerated was among just 200 accredited press outlets at this year’s BIO, where capital felt scarcer, more selective, and more global — and investors’ questions moved earlier in the development timeline. Here is a pulse check from San Diego, across five companies working the gap between promise and proof.
Strategic Partnership: Iconovo’s Long-Term Collaboration with Lonza
How does a small inhalation specialist become a trusted global player? Iconovo’s Anders Månsson shares why deep, strategic partnerships with leaders like Lonza can transform both technology access and investor confidence.
Driven by Purpose: Voices from the Swedish Pavilion at BIO International 2026
As this year’s BIO International Convention embraced the theme Driven by Purpose, Ventures Accelerated sent a flying reporter to the Swedish Pavilion to meet the innovators behind Sweden’s life science companies.
Evolving Landscape of Global Healthcare Partnerships
Kristel Sauter talks about the connection dynamics in BIO-International 2026, as a global gathering point and shares insights on the latest acquisitions trends and partnership potential.
Modelling the future of Biotech Operations
Biotech’s future won’t be won by a single business model. In this editorial, Anders Månsson breaks down the strengths and weaknesses of asset, platform, and service models—and argues that the real winners will be hybrids that blend all three to stay financeable, scalable, and resilient in tougher markets.
OnDosis continues to drive the conversation on individualized dosing in ADHD
Achieving the right dose remains one of the biggest challenges in ADHD treatment. Discover how individualized dose optimization could improve treatment continuity, patient adherence, and long-term outcomes.
The Hidden Value of Nordic Life Science Innovation
Many Nordic life science companies have world-class science, yet struggle to attract the attention they deserve. In this exclusive Venture Road UK conversation, investor Altar Munis reveals what truly matters to UK investors—and why the right story can be just as important as the science itself.
Connecting the Golden Triangle and Nordics: Venture Road UK 2026 Kick Off
Discover how leading players from the UK and Nordic life sciences ecosystems are joining forces to accelerate innovation and advance the future of Precision Health.
Targeted Cancer Therapies with Avacta: From Scientific Story to Patient Impact
Last Thursday during Venture Road UK, companies from across the Nordics and the UK pitched in front of a mixed audience of investors and industry partners. Our warm congratulations to the winner of the pitch session, Christina Coughlin, CEO of Avacta, who is working on targeted cancer therapy delivery to improve efficacy while reducing side effects for patients.
Beyond the Convention Floor: Positioning Nordic Life Science Leaders for BIO International 2026
As BIO International 2026 approaches, standing out requires more than breakthrough science. Discover how Ventures Accelerated helps Nordic life science companies transform visibility into strategic partnerships through targeted positioning, exclusive interviews, and global outreach.
Beyond Science Excellence: Using IP and Strategy to Reach Successful Life Science Exits
Through our new partnership with AWA Sweden, we explore how strategic IP management can strengthen valuation, support funding, and prepare companies for successful partnerships and exits.
The Human Side of Biotech Partnering
What makes a biotech partnership truly successful ? Beyond term sheets and deal structures, the strongest collaborations are built on trust, alignment, and a shared vision. Discover the human side of biotech partnering.
Meet Our Accelerators
Meet Julie Ames, an expert in corporate communications, investor relations, and leadership. With a background spanning the Federal Reserve Board to major life sciences companies like Thermo Fisher Scientific, she brings deep experience at the intersection of finance, biotech, and strategic communication.
Redefining the Possible: How Just – Evotec Biologics is Decoding the Future of Biomanufacturing
At InterPhex 2026, one challenge stands out: scaling complex biologics affordably. Just-Evotec Biologics is redefining the model with AI-driven design and continuous manufacturing — reshaping access to next-generation therapies.
The Beauty of Innovation: an episode of the Discovery Matters podcast
In this episode of Discovery Matters by Cytiva, innovation is explored from both a scientific and deeply human perspective. Insights are shared on how AI, precision partnering, empathy, and behavioural insight are reshaping life sciences.
Starting With the End in Mind
Explore how life science companies can benefit from thinking about their end goals from the very beginning. Featuring insights from industry experts, it highlights how early decisions around IP, strategy, and structure can shape long-term outcomes. A concise look at the perspectives shared ahead of The End Game seminar.
Spring Salon: Where Community and Art Meet
The Spring Salon marks the arrival of spring in the Nordics, an evening of connection, renewal, and art for the life science community. Join us on April 28 at Skeppsbron 10 as our space transforms into a gallery featuring Emma Jelk and Jullianne Jabol.
Precision Immunotherapy in Late-Line mCRC: An Interview with Prof. Sebastian Stintzing on OBERTO-202 at Charité Berlin
In metastatic colorectal cancer, where treatment options are limited, new approaches are urgently needed. At Charité Berlin, Professor Sebastian Stintzing is advancing a novel combination of immunotherapy and personalized vaccination—aiming to improve outcomes through smarter patient selection and innovative trial design.